|
Market Closed -
Sao Paulo
16:09:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 75.00 BRL | -7.06% |
|
+8.38% | +13.71% |
| 09-16 | Sling Therapeutics raises $123 million to advance thyroid eye disease drug | RE |
| 09-15 | Amgen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM |
| Market Cap | 208B 1,077B 182B 172B 156B 292B 20,006B 293B 2,056B 794B 10,171B 783B 766B 32,728B | P/E 2026 * |
24.4x | P/E 2027 * | 21.9x |
|---|---|---|---|---|---|
| Enterprise Value | 250B 1,291B 218B 206B 187B 350B 23,987B 352B 2,465B 951B 12,195B 939B 918B 39,240B | EV / Sales 2026 * |
6.42x | EV / Sales 2027 * | 6.07x |
| Free-Float |
99.77% | Yield 2026 * |
2.62% | Yield 2027 * | 2.76% |
Last Transcript: Amgen Inc.
| 1 day | -7.06% | ||
| 1 week | +8.38% | ||
| Current month | -5.96% | ||
| 1 month | -5.18% | ||
| 3 months | +20.40% | ||
| 6 months | +14.54% | ||
| Current year | +13.71% |
| 1 week | 68.98 |  | 80.47 |
| 1 month | 68.98 | | 82.26 |
| Current year | 48.4 | | 83.38 |
| 1 year | 48.4 | | 83.38 |
| 3 years | 45.12 | | 83.38 |
| 5 years | 37.52 | | 83.38 |
| 10 years | 15.78 | | 83.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 2023-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.06% | +8.38% | - | - | 208B | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,028B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 466B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 346B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 266B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 259B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 208B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 191B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 186B | |
| Average | -0.52% | +3.26% | +26.15% | +45.30% | 400.19B | |
| Weighted average by Cap. | -0.17% | +3.09% | +35.15% | +61.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.94B 201B 33.95B 32.06B 29.11B 54.55B 3,736B 54.77B 384B 148B 1,900B 146B 143B 6,112B | 40.23B 208B 35.08B 33.13B 30.08B 56.36B 3,861B 56.6B 397B 153B 1,963B 151B 148B 6,315B |
| Net income | 8.68B 44.83B 7.57B 7.15B 6.49B 12.16B 833B 12.21B 85.59B 33.03B 423B 32.6B 31.88B 1,362B | 9.34B 48.25B 8.15B 7.69B 6.98B 13.09B 896B 13.14B 92.14B 35.55B 456B 35.09B 34.31B 1,466B |
| Net Debt | 41.49B 214B 36.18B 34.16B 31.02B 58.11B 3,981B 58.36B 409B 158B 2,024B 156B 152B 6,512B | 35.82B 185B 31.23B 29.49B 26.78B 50.17B 3,437B 50.38B 353B 136B 1,747B 135B 132B 5,622B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | R$75.00 | +7.82% | 215 |
| 26-09-17 | R$69.56 | +0.49% | 359 |
| 26-09-16 | R$69.22 | -13.98% | 567 |
| 26-09-15 | R$80.47 | +14.63% | 368 |
| 26-09-14 | R$70.20 | +1.45% | 49 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
